Literature DB >> 9300246

Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins.

M Passarelli1, S Catanozi, E R Nakandakare, J C Rocha, R E Morton, A F Shimabukuro, E C Quintão.   

Abstract

Alterations in the reverse cholesterol transport system have been described in diabetic mellitus patients in several but not all studies. Furthermore, recently published investigations suggest that a faster "in vitro" transfer rate of cholesteryl ester from high density lipoproteins to apoB-containing lipoproteins could be solely ascribed to variation of the plasma lipoprotein composition and concentration in the diabetic state. The present study analysed the influence of lipoprotein glycation on the cholesteryl ester transfer protein-mediated transfer of esterified cholesterol from high density lipoprotein and its subfractions to lighter density lipoproteins. For this purpose two sets of "in vitro" experiments were carried out utilizing:1) plasma lipoproteins drawn from diabetic and from normal subjects and; 2) normal lipoproteins or partially purified cholesteryl ester transfer protein submitted to "in vitro" glycation. The transfer rate of 14C-cholesteryl ester labelled HDL subfractions to low or very low density lipoproteins was measured in all experiments. After incubations with plasma d > 1.21 g/ml or with purified cholesteryl ester transfer protein, apoB-containing lipoproteins were precipitated with a dextran sulfate/MgCl2 solution. The "in vitro" glycation of the partially purified cholesteryl ester transfer protein, markedly impaired its activity. However, greater transfer rates were observed when lipoproteins from diabetic individuals or the "in vitro" glycated lipoproteins were utilized. This effect was attributed to glycation of the protein component of HDL. In conclusion, lipoprotein glycation elicits an enrichment of the apoB-containing lipoproteins with cholesteryl ester that is likely related to the premature atherosclerosis in patients with poorly controlled diabetes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300246     DOI: 10.1007/s001250050791

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Effect of the nonenzymatic glycosylation of high density lipoprotein-3 on the cholesterol ester transfer protein activity.

Authors:  B Lemkadem; D Loiseau; G Larcher; Y Malthiery; F Foussard
Journal:  Lipids       Date:  1999-12       Impact factor: 1.880

2.  Whole-exome sequencing in maya indigenous families: variant in PPP1R3A is associated with type 2 diabetes.

Authors:  Katy Sánchez-Pozos; María Guadalupe Ortíz-López; Bárbara I Peña-Espinoza; María de Los Ángeles Granados-Silvestre; Verónica Jiménez-Jacinto; Jérôme Verleyen; Fasil Tekola-Ayele; Alejandro Sanchez-Flores; Marta Menjivar
Journal:  Mol Genet Genomics       Date:  2018-06-11       Impact factor: 3.291

3.  The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase.

Authors:  E Nobecourt; M J Davies; B E Brown; L K Curtiss; D J Bonnet; F Charlton; A S Januszewski; A J Jenkins; P J Barter; K-A Rye
Journal:  Diabetologia       Date:  2007-01-10       Impact factor: 10.122

Review 4.  Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease.

Authors:  Kerry-Anne Rye
Journal:  Clin Exp Nephrol       Date:  2013-09-20       Impact factor: 2.801

5.  Relationship between lipid profiles and kidney function in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; O Heikkilä; K Pettersson-Fernholm; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

Review 6.  The role of CETP inhibition in dyslipidemia.

Authors:  Karim El Harchaoui; Wim A van der Steeg; Erik S G Stroes; John J P Kastelein
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

7.  Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes.

Authors:  Alessandra Gatti; Marianna Maranghi; Simonetta Bacci; Claudio Carallo; Agostino Gnasso; Elisabetta Mandosi; Mara Fallarino; Susanna Morano; Vincenzo Trischitta; Sebastiano Filetti
Journal:  Diabetes Care       Date:  2009-06-01       Impact factor: 19.112

8.  Inhibiting low-density lipoprotein glycation ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats.

Authors:  Margo P Cohen; Elizabeth A Shea; Van-Yu Wu
Journal:  Metabolism       Date:  2009-11-18       Impact factor: 8.694

Review 9.  Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications.

Authors:  Margo P Cohen; Fuad N Ziyadeh; Sheldon Chen
Journal:  J Lab Clin Med       Date:  2006-05

10.  Advanced glycation in macrophages induces intracellular accumulation of 7-ketocholesterol and total sterols by decreasing the expression of ABCA-1 and ABCG-1.

Authors:  Rodrigo T Iborra; Adriana Machado-Lima; Gabriela Castilho; Valeria S Nunes; Dulcinéia S P Abdalla; Edna R Nakandakare; Marisa Passarelli
Journal:  Lipids Health Dis       Date:  2011-09-29       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.